Answers are grounded in this paper and cite their sources.
This paper evaluates the reasons behind the rise in the use of proton beam for prostate cancer, the economics drivers behind it, and the evidence that exists to support it. It concludes that clinical outcome data underlying the notion that this is a superior treatment remains sparse and discusses what is needed to fill in the gaps.
No takes yet. Share an insight, caveat, or question.
Anthony L. Zietman (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: